Grade My Investments
HomeFree Stock Grades › SPRY

ARS Pharmaceuticals, Inc. (SPRY) Stock Grade

SPRY · Healthcare

C-
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.1B
P/E Ratio
Revenue Growth (YoY)
-5.5%
Net Margin
-203.3%
Return on Equity
Dividend Yield
None

About ARS Pharmaceuticals, Inc.'s fundamentals

ARS Pharmaceuticals is a biotechnology company with a market capitalization of $1.1 billion that reported a net loss in its latest annual statement, reflected in its negative net margin of -203.3%. The company experienced a year-over-year revenue decline of 5.5%, indicating contraction in sales during the period. As a loss-making biotech firm, the company does not pay a dividend and traditional profitability metrics like price-to-earnings ratio and return on equity are not applicable.

Track SPRY free — no credit card required. Live grade + monthly AI report →